drugset / Trial / NCT01004159
Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
NaSingle-groupOpen-labelTreatment
Summary
This study is being performed to test if the use of high dose of cetuximab in combination with irinotecan overcomes the resistance seen with standard dose of cetuximab plus irinotecan in patients with wild type KRS tumors that have advanced colon or rectal cancer
Timeline
- Start
- 2009-09
- Primary completion
- 2012-05
- Completion
- 2012-05
Outcome
Outcome not reported
Stopped: “former PI left institute”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | — |
| Subject | Irinotecan | Small molecule | — | — |